Adjunctive Clavulanic Acid Abolishes the Cefazolin Inoculum Effect in an Experimental Rat Model of Methicillin-Sensitive Staphylococcus aureus Endocarditis

Antimicrobial Agents and Chemotherapy
William R MillerB E Murray

Abstract

We tested the ability of clavulanic acid to restore the efficacy of cefazolin against Staphylococcus aureus TX0117, which exhibits the cefazolin inoculum effect (CzIE). In the rat infective endocarditis model, the coadministration of cefazolin plus clavulanic acid resulted in a significant reduction of bacterial counts (7.1 ± 0.5 log10 CFU/g) compared to that with cefazolin alone (2 ± 0.6 log10 CFU/g; P < 0.0001). The addition of a β-lactamase inhibitor may be a viable strategy for overcoming the CzIE.

References

Sep 1, 1982·Antimicrobial Agents and Chemotherapy·D AdamP Koeppe
Oct 15, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Esteban C NanniniBarbara E Murray
May 23, 2012·Emerging Infectious Diseases·James L HadlerMatthew L Cartter
Sep 18, 2013·JAMA Internal Medicine·Raymund DantesUNKNOWN Emerging Infections Program–Active Bacterial Core Surveillance MRSA Surveillance Investigators
Jul 8, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Shinwon LeeShin-Woo Kim
May 29, 2015·Clinical Microbiology Reviews·Steven Y C TongVance G Fowler
Apr 6, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jennifer S McDanelMarin L Schweizer
Jul 12, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S LeeUNKNOWN Korea INfectious Diseases (KIND) study group

❮ Previous
Next ❯

Citations

Jul 15, 2020·Antimicrobial Agents and Chemotherapy·J Chase McNeilStephanie Fritz
Jun 7, 2019·The Journal of Antimicrobial Chemotherapy·Justin R Lenhard, Zackery P Bulman
Dec 30, 2020·Chemical Reviews·Jed F Fisher, Shahriar Mobashery

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.